Cheryl N. McMahill-Walraven, MSW, PhD

President & CEO
Glade Oak Inc
Royersford, Pennsylvania, United States

Disclosure information not submitted.

Presentation(s):

• 1D-02 - Risk of Incident Supraventricular Tachycardia Following Exposure to Recombinant Zoster Vaccine in Adults ≥50 Years of Age in the United States

  Sunday, August 24, 2025
  10:45 AM - 11:00 AM ET

• 1D-05 - Rapid Surveillance Study to Evaluate Safety of Respiratory Syncytial Virus (RSV) Vaccine (ABRYSVO™) Exposure During Pregnancy in the United States

  Sunday, August 24, 2025
  11:30 AM - 11:45 AM ET

• 5C-02 - Quantitative Bias Analysis to Assess Impact of Outcome Misclassification in a Claims-based COVID-19 Vaccine Safety Study in the US

  Tuesday, August 26, 2025
  8:45 AM - 9:00 AM ET

• 5C-04 - An Observational Postauthorization Safety Study to Assess Adverse Events of Special Interest in Recipients of Ad26.COV2.S in the United States

  Tuesday, August 26, 2025
  9:15 AM - 9:30 AM ET

• 5C-06 - Incidence Rates of Myocarditis/Pericarditis after Pfizer-BioNTech COVID-19 Vaccine in the United States: Interim Results From a Postapproval Safety Study, Primary Series Analysis

  Tuesday, August 26, 2025
  9:45 AM - 10:00 AM ET